Last reviewed · How we verify
AL101
AL101 is an inhibitor of the PI3K/AKT/mTOR pathway.
AL101 is an inhibitor of the PI3K/AKT/mTOR pathway. Used for Solid tumors with PI3K/AKT/mTOR pathway alterations.
At a glance
| Generic name | AL101 |
|---|---|
| Also known as | BMS 906024, AL 101, AL-101, BM-0018, BM0018 |
| Sponsor | Ayala Pharmaceuticals, Inc, |
| Drug class | PI3K/AKT/mTOR inhibitor |
| Target | PI3K/AKT/mTOR pathway |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting the PI3K/AKT/mTOR pathway, AL101 exerts its anti-tumor effects. This pathway is crucial for cell proliferation and survival, and its inhibition can lead to apoptosis in cancer cells.
Approved indications
- Solid tumors with PI3K/AKT/mTOR pathway alterations
Common side effects
- Diarrhea
- Fatigue
- Nausea
- Vomiting
Key clinical trials
- Open-label Extension Study in Participants With Early Alzheimer's Disease (PHASE2)
- Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease (PHASE2)
- AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer (PHASE1)
- COVID-19 Vaccinations With a Sweepstakes (NA)
- Service Dog Training Program for Military Veterans With PTSD (NA)
- A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer (PHASE2)
- A Study Of AL101In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations (PHASE2)
- A Phase 1 First in Human Study to Assess Safety and Tolerability of AL101 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AL101 CI brief — competitive landscape report
- AL101 updates RSS · CI watch RSS
- Ayala Pharmaceuticals, Inc, portfolio CI